Predictive Oncology Inc. (POAI)
USD 0.73
(-1.35%)
USD 0.73
(-1.35%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 2.85 Million USD | 1484.31% |
| 2022 | 180.31 Thousand USD | -79.49% |
| 2021 | 879.32 Thousand USD | -85.03% |
| 2020 | 5.87 Million USD | 6.32% |
| 2019 | 5.52 Million USD | 237.97% |
| 2018 | 1.63 Million USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | 0.0% |
| 2015 | - USD | -100.0% |
| 2014 | 937.42 Thousand USD | 234.79% |
| 2013 | 280 Thousand USD | -76.08% |
| 2012 | 1.17 Million USD | -30.56% |
| 2011 | 1.68 Million USD | 57.09% |
| 2010 | 1.07 Million USD | 465.58% |
| 2009 | 189.72 Thousand USD | -35.91% |
| 2008 | 296.02 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 2.6 Million USD | -8.79% |
| 2024 Q2 | 2.69 Million USD | 3.61% |
| 2023 FY | 2.85 Million USD | 1484.31% |
| 2023 Q4 | 2.85 Million USD | -9.58% |
| 2023 Q3 | 3.15 Million USD | 6.57% |
| 2023 Q2 | 2.96 Million USD | -1.98% |
| 2023 Q1 | 3.02 Million USD | 1577.32% |
| 2022 FY | 180.31 Thousand USD | -79.49% |
| 2022 Q4 | 180.31 Thousand USD | -19.95% |
| 2022 Q3 | 225.24 Thousand USD | -57.91% |
| 2022 Q2 | 535.19 Thousand USD | -23.84% |
| 2022 Q1 | 702.75 Thousand USD | -20.08% |
| 2021 Q4 | 879.32 Thousand USD | -14.28% |
| 2021 FY | 879.32 Thousand USD | -85.03% |
| 2021 Q3 | 1.02 Million USD | -14.16% |
| 2021 Q1 | 1.28 Million USD | -78.08% |
| 2021 Q2 | 1.19 Million USD | -7.2% |
| 2020 Q1 | 6.56 Million USD | 18.79% |
| 2020 Q3 | 7.55 Million USD | 27.11% |
| 2020 Q4 | 5.87 Million USD | -22.2% |
| 2020 Q2 | 5.94 Million USD | -9.49% |
| 2020 FY | 5.87 Million USD | 6.32% |
| 2019 Q3 | 5.35 Million USD | 11.28% |
| 2019 Q2 | 4.81 Million USD | 56.35% |
| 2019 FY | 5.52 Million USD | 237.97% |
| 2019 Q1 | 3.07 Million USD | 88.33% |
| 2019 Q4 | 5.52 Million USD | 3.14% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2018 Q3 | 1 Million USD | 0.0% |
| 2018 Q4 | 1.63 Million USD | 62.73% |
| 2018 FY | 1.63 Million USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2016 FY | - USD | 0.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q3 | - USD | 0.0% |
| 2016 Q2 | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | -100.0% |
| 2015 Q2 | 933.07 Thousand USD | 2.85% |
| 2015 FY | - USD | -100.0% |
| 2015 Q1 | 907.24 Thousand USD | -3.22% |
| 2014 Q3 | 1.16 Million USD | 1341.84% |
| 2014 Q1 | - USD | -100.0% |
| 2014 FY | 937.42 Thousand USD | 234.79% |
| 2014 Q2 | 81.12 Thousand USD | 0.0% |
| 2014 Q4 | 937.42 Thousand USD | -19.86% |
| 2013 Q4 | 280 Thousand USD | 0.0% |
| 2013 Q1 | 975.88 Thousand USD | -16.63% |
| 2013 Q2 | 1.57 Million USD | 61.51% |
| 2013 Q3 | - USD | -100.0% |
| 2013 FY | 280 Thousand USD | -76.08% |
| 2012 Q4 | 1.17 Million USD | -6.01% |
| 2012 Q2 | 1.29 Million USD | -26.96% |
| 2012 Q1 | 1.77 Million USD | 5.22% |
| 2012 FY | 1.17 Million USD | -30.56% |
| 2012 Q3 | 1.24 Million USD | -3.86% |
| 2011 Q2 | 1.32 Million USD | 4.55% |
| 2011 Q1 | 1.26 Million USD | 18.24% |
| 2011 FY | 1.68 Million USD | 57.09% |
| 2011 Q3 | 1.38 Million USD | 4.76% |
| 2011 Q4 | 1.68 Million USD | 21.31% |
| 2010 Q1 | 391.99 Thousand USD | 106.61% |
| 2010 Q3 | 582.29 Thousand USD | 45.49% |
| 2010 Q2 | 400.23 Thousand USD | 2.1% |
| 2010 Q4 | 1.07 Million USD | 84.28% |
| 2010 FY | 1.07 Million USD | 465.58% |
| 2009 FY | 189.72 Thousand USD | -35.91% |
| 2009 Q4 | 189.72 Thousand USD | -35.12% |
| 2009 Q3 | 292.44 Thousand USD | 0.0% |
| 2008 FY | 296.02 Thousand USD | 0.0% |
| 2008 Q4 | 296.02 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 85.7 Million USD | 96.667% |
| AngioDynamics, Inc. | 5.91 Million USD | 51.694% |
| AtriCure, Inc. | 74.49 Million USD | 96.165% |
| Avinger, Inc. | 15.39 Million USD | 81.443% |
| Azenta, Inc. | 60.43 Million USD | 95.273% |
| BioLife Solutions, Inc. | 42.69 Million USD | 93.308% |
| The Cooper Companies, Inc. | 2.56 Billion USD | 99.889% |
| Daxor Corporation | 755.65 Thousand USD | -278.056% |
| Ekso Bionics Holdings, Inc. | 7.16 Million USD | 60.145% |
| Femasys Inc. | 6.7 Million USD | 57.367% |
| GlucoTrack, Inc. | 196 Thousand USD | -1357.558% |
| Harvard Bioscience, Inc. | 42.77 Million USD | 93.321% |
| Hologic, Inc. | 2.53 Billion USD | 99.887% |
| ICU Medical, Inc. | 1.7 Billion USD | 99.832% |
| Intuitive Surgical, Inc. | 89.8 Million USD | 96.819% |
| KORU Medical Systems, Inc. | 4.44 Million USD | 35.731% |
| LeMaitre Vascular, Inc. | 19.09 Million USD | 85.039% |
| Innovative Eyewear, Inc. | - USD | -Infinity% |
| Innovative Eyewear, Inc. | - USD | -Infinity% |
| Masimo Corporation | 970 Million USD | 99.705% |
| Microbot Medical Inc. | 231 Thousand USD | -1136.716% |
| Meihua International Medical Technologies Co., Ltd. | 7.33 Million USD | 61.032% |
| Merit Medical Systems, Inc. | 891.35 Million USD | 99.679% |
| Nephros, Inc. | 1.83 Million USD | -55.6% |
| NovoCure Limited | 596.24 Million USD | 99.521% |
| NEXGEL, Inc. | 2.79 Million USD | -2.102% |
| NEXGEL, Inc. | 2.79 Million USD | -2.102% |
| Singular Genomics Systems, Inc. | 75.28 Million USD | 96.205% |
| OraSure Technologies, Inc. | 13.5 Million USD | 78.845% |
| Pro-Dex, Inc. | 13.54 Million USD | 78.912% |
| Pulse Biosciences, Inc. | 9.14 Million USD | 68.758% |
| Precision Optics Corporation, Inc. | 3.43 Million USD | 16.819% |
| QuidelOrtho Corporation | 2.61 Billion USD | 99.891% |
| Repligen Corporation | 711.8 Million USD | 99.599% |
| Sanara MedTech Inc. | 11.79 Million USD | 75.774% |
| STAAR Surgical Company | 35.83 Million USD | 92.028% |
| Sharps Technology, Inc. | - USD | -Infinity% |
| Utah Medical Products, Inc. | 342 Thousand USD | -735.326% |
| DENTSPLY SIRONA Inc. | 2.29 Billion USD | 99.876% |
| Jin Medical International Ltd. | 4.11 Million USD | 30.542% |